Roche has revealed that its bispecific factor IXa- and factor X-directed antibody Hemlibra (emicizumab) has been approved by the European Commission (EC) for routine prophylaxis of bleeding episodes in people with...
MSD has made it known that its cancer immunotherapy Keytruda (pembrolizumab) failed to meet its primary endpoint in a Phase 3 study evaluating its efficacy as a monotherapy for the second- or third-line treatment of...
Het nieuwe jaar is begonnen en als het goed is heb je jouw marketing- en contentstrategie voor dit jaar al op de plank, toch? Maar heb jij hierin ook rekening gehouden met de belangrijkste ontwikkelingen bij LinkedIn?
‘Content Frenemies, the human touch in a tech driven world’. Dit is de spannende titel van het zesde event dat Albert Jan Huisman en Bert van Loon van CMFF (Content Marketing Fast Forward) organiseerden, donderdag 11...
Content marketing This week Robert Rose takes on the truth – what is vs. what ought to be. He also explores the advertising-and-data problem and talks to the authors of a new book about the internal workings of content...
Is Speed and Not AI Technology the Real Enemy in Marketing? More than 25 years ago, I managed one of the most innovative types of companies on the planet – a website development agency (yes, really). Remember, this was...
Falling numbers of General Practitioners (GPs) in the UK are due to “concerns regarding professional risk in delivering care in an increasingly complex health environment”, and a feeling general practice-based primary...
A miniaturized version of a musical instrument that could be used to improve the quality of medical images has been manufactured by researchers at the University of Strathclyde.
A new recommendation from NICE means that thousands of patients in England and Wales will be able to receive Abbvie’s Venclyxto (venetoclax) in combination with Genentech’s Rituxan (rituximab) on the NHS as a treatment...
We gebruiken cookies om ervoor te zorgen dat onze website zo soepel mogelijk draait. Als u doorgaat met het gebruiken van de website, gaan we er vanuit dat u ermee instemt.